stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Revenue
Xeris Biopharma Holdings, Inc.'s revenue for fiscal 2025 was $291.8M, up 43.7% from $203.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $368.3M. Over the past ten years it has ranged from $1.1M (fiscal 2016) to $291.8M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 9 consecutive fiscal years. Xeris Biopharma Holdings, Inc. ranks 31st of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $291.8M | 43.72% |
| FY2024 | $203.1M | 23.89% |
| FY2023 | $163.9M | 48.68% |
| FY2022 | $110.2M | 122.32% |
| FY2021 | $49.6M | 142.67% |
| FY2020 | $20.4M | 650.73% |
| FY2019 | $2.7M | 12.34% |
| FY2018 | $2.4M | 55.72% |
| FY2017 | $1.6M | 44.74% |
| FY2016 | $1.1M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $107.2M | 16.42% |
| Jun 2026 | $92.1M | 10.79% |
| Mar 2026 | $83.1M | (3.12%) |
| Dec 2025 | $85.8M | 15.36% |
| 33 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $10.1B |
| PRGO Perrigo Company plc compare | $4.1B |
| PBH Prestige Consumer Healthcare Inc. compare | $1.2B |
| TRLV Trulieve Cannabis Corp. compare | $1.1B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $961.5M |
| XERS Xeris Biopharma Holdings, Inc. | $368.3M |
| ALVO Alvotech compare | $293.3M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $87.4M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on XERS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement